Carcinogens, Mutagens and Teratogens

Overview
Carcinogens, mutagens and teratogens are the three classic categories of chronic, delayed-effect toxicants that appear repeatedly in the Industrial Hygiene and Occupational Health domain of the BCSP Associate Safety Professional (ASP) exam. They are grouped together because each produces harm that is often invisible at the time of exposure, may not appear for years or even a generation, and is frequently irreversible. Because the consequences are so severe, regulators and professional bodies treat these agents differently from ordinary irritants or acute toxins: lower hazard communication thresholds, special OSHA standards, mandatory medical surveillance and an assumption in many cases that there is no completely safe level of exposure.

Why This Topic Is Important
1. Regulatory weight. OSHA has a dedicated standard for 13 carcinogens (29 CFR 1910.1003) and substance-specific standards for agents such as asbestos, benzene, vinyl chloride, formaldehyde, hexavalent chromium, methylene chloride, cadmium, ethylene oxide, lead and 1,3-butadiene. The Hazard Communication Standard (29 CFR 1910.1200) requires that carcinogens be listed on a Safety Data Sheet at concentrations of 0.1 percent or greater, versus 1 percent for most other health hazards.
2. Severity and irreversibility. Cancer, heritable genetic damage and birth defects are among the worst outcomes a workplace exposure can cause, and they typically cannot be reversed once they occur.
3. Long latency. Occupational cancers commonly appear 10 to 40 years after exposure, so the safety professional must prevent exposure now to protect people decades later, and must understand exposure history to interpret disease clusters.
4. Reproductive health. Protecting workers of reproductive age (both sexes) is a growing area of practice and a frequent source of exam questions about fetal protection policies, which were limited by the U.S. Supreme Court (UAW v. Johnson Controls, 1991) because exclusion of fertile women was found to be discriminatory.
5. Exam frequency. Classification systems (IARC, NTP, ACGIH, GHS), classic agent-disease pairings and definitional distinctions between the three terms are highly testable and are among the most reliable points you can earn.

What They Are: Core Definitions
Carcinogen: Any agent (chemical, physical or biological) capable of causing or increasing the incidence of cancer, which is uncontrolled cell growth with the ability to invade other tissues. Examples include asbestos, benzene, vinyl chloride, hexavalent chromium, arsenic, beryllium, cadmium, formaldehyde, crystalline silica, wood dust, ionizing radiation, ultraviolet radiation, radon and the hepatitis B virus.
Mutagen: Any agent that causes a permanent change (mutation) in the genetic material (DNA) of a cell. If the change occurs in a somatic (body) cell it may lead to cancer in the exposed individual; if it occurs in a germ cell (sperm or egg) it may be passed to future generations as a heritable defect. Examples include ionizing radiation, ethylene oxide, benzene, alkylating agents, aflatoxin and many nitrosamines.
Teratogen: Any agent that causes structural or functional abnormalities in a developing embryo or fetus (birth defects) when the mother is exposed during pregnancy. Teratogens act on the developing organism, not necessarily through DNA damage. Examples include thalidomide, lead, methylmercury (Minamata disease), ethanol (fetal alcohol syndrome), ionizing radiation, isotretinoin, carbon monoxide, certain glycol ethers, some anesthetic gases, rubella virus and diethylstilbestrol (DES).

The broader modern term you may see is CMR (carcinogenic, mutagenic or toxic to reproduction). Reproductive toxicants are a wider category that includes teratogens but also agents that reduce fertility in men or women (for example, dibromochloropropane or DBCP caused sterility in male workers) and agents that harm infants through breast milk.

How It Works: Mechanisms
Carcinogenesis is usually described as a multistage process:
1. Initiation: a genotoxic agent damages DNA, producing a mutation in a critical gene (such as an oncogene or tumor suppressor gene). This step is rapid and essentially irreversible.
2. Promotion: a promoter stimulates the initiated cell to proliferate. Promoters (for example, phorbol esters or chronic irritation) do not damage DNA directly; their effect is reversible and generally shows a threshold.
3. Progression: cells acquire further genetic changes, become malignant and gain the ability to invade and metastasize.
Carcinogens are divided into genotoxic (directly or after metabolic activation react with DNA; assumed to have no threshold, modeled with a linear no-threshold dose-response) and non-genotoxic or epigenetic (cause cancer through hormonal effects, cytotoxicity and regenerative proliferation, immune suppression or persistent irritation; generally assumed to have a threshold). Many chemicals are procarcinogens that require metabolic activation by liver enzymes (cytochrome P450) to become the ultimate carcinogen; benzo[a]pyrene and vinyl chloride are classic examples. Cocarcinogens enhance the effect of a carcinogen, as seen in the synergism between asbestos and cigarette smoking (lung cancer risk is multiplied, not simply added).

Mutagenesis involves changes to DNA such as point mutations (base substitutions, insertions, deletions), chromosomal aberrations (breaks, translocations) and changes in chromosome number (aneuploidy). Cells have DNA repair systems, so a dose that overwhelms repair capacity is more likely to leave permanent damage. All genotoxic carcinogens are mutagens, but not every mutagen has been shown to cause cancer, and non-genotoxic carcinogens are not mutagens. Mutagens are often used as a screening signal for potential carcinogenicity.

Teratogenesis follows well-established principles (often attributed to James Wilson):
1. Susceptibility depends on the developmental stage at the time of exposure. The pre-implantation period (roughly the first two weeks) tends to follow an all-or-none rule (the embryo dies or recovers fully). The embryonic period (approximately weeks 3 through 8), when organogenesis occurs, is the window of greatest sensitivity for major structural defects. The fetal period (week 9 to birth) is more associated with growth retardation and functional deficits, especially of the central nervous system.
2. Susceptibility depends on the genotype of the mother and the conceptus.
3. Teratogens act through specific mechanisms (cell death, altered cell migration, interference with signaling, hypoxia, nutrient deprivation).
4. Outcomes include death, malformation, growth retardation and functional disorder.
5. Access to the conceptus depends on the nature of the agent: ability to cross the placenta, molecular size, lipid solubility, ionization.
6. Effects increase with dose, and teratogens are generally considered to have a threshold below which no effect is observed.
Note also transplacental carcinogens such as DES, which caused vaginal cancer in daughters of exposed women, and the role of paternal exposure (for example, lead carried home on clothing or effects on sperm).

Classification Systems You Must Know
IARC (International Agency for Research on Cancer, part of WHO):
Group 1: Carcinogenic to humans (sufficient human evidence). Examples: asbestos, benzene, arsenic, vinyl chloride, formaldehyde, hexavalent chromium, crystalline silica, ionizing radiation, tobacco smoke, wood dust, outdoor air pollution, solar radiation.
Group 2A: Probably carcinogenic to humans (limited human evidence, sufficient animal evidence). Examples: diesel engine exhaust was moved to Group 1 in 2012; current 2A examples include glyphosate, acrylamide, shift work involving circadian disruption and lead compounds (inorganic).
Group 2B: Possibly carcinogenic to humans (limited human evidence, less than sufficient animal evidence).
Group 3: Not classifiable as to carcinogenicity in humans.
Group 4 (probably not carcinogenic) was eliminated in 2019; exam materials may still reference it, so recognize it but know it is no longer used.

NTP (U.S. National Toxicology Program, Report on Carcinogens): Two categories only: Known to be a human carcinogen and Reasonably anticipated to be a human carcinogen.

ACGIH (TLV booklet notations):
A1: Confirmed human carcinogen.
A2: Suspected human carcinogen.
A3: Confirmed animal carcinogen with unknown relevance to humans.
A4: Not classifiable as a human carcinogen.
A5: Not suspected as a human carcinogen.
ACGIH also uses the SEN (sensitizer) and Skin notations, which are frequently confused with carcinogen notations on the exam.

NIOSH: Uses the designation Ca (potential occupational carcinogen) in the Pocket Guide and generally recommends reducing exposure to the lowest feasible concentration (LFC).

EPA: Uses descriptive categories under its cancer guidelines: carcinogenic to humans; likely to be carcinogenic to humans; suggestive evidence; inadequate information; not likely to be carcinogenic. Older EPA letter groups (A, B1, B2, C, D, E) may still appear.

OSHA: OSHA does not maintain a comprehensive carcinogen list; instead it regulates specific carcinogens through substance-specific standards in 29 CFR 1910.1001 through 1910.1052 and the 13 carcinogens standard (1910.1003), which requires regulated areas, closed systems, decontamination, signage and medical surveillance. For Hazard Communication, a chemical is treated as a carcinogen if it is listed by IARC (Group 1 or 2A, and 2B in most interpretations), NTP or regulated by OSHA.

GHS / HazCom 2012 Health Hazard Classes:
Carcinogenicity: Category 1A (known human carcinogen), Category 1B (presumed, based on animal data), Category 2 (suspected). Hazard statements: H350 (May cause cancer) for Category 1; H351 (Suspected of causing cancer) for Category 2.
Germ cell mutagenicity: Category 1A (known to cause heritable mutations in humans), 1B (presumed), 2 (suspected). H340 (May cause genetic defects) for Category 1; H341 (Suspected of causing genetic defects) for Category 2.
Reproductive toxicity: Category 1A (known), 1B (presumed), 2 (suspected), plus an additional category for effects on or via lactation. H360 (May damage fertility or the unborn child); H361 (Suspected of damaging fertility or the unborn child); H362 (May cause harm to breast-fed children).
All three classes use the health hazard pictogram (silhouette of a person with a starburst on the chest). Category 1 uses the signal word Danger; Category 2 uses Warning. SDS cutoff: 0.1 percent for Category 1 carcinogens, mutagens and reproductive toxicants; 1 percent for Category 2 carcinogens (0.3 percent for Category 2 reproductive toxicants under GHS, though OSHA permits 1 percent in some cases). For exam purposes, remember the headline rule: 0.1 percent for carcinogens.

How These Agents Are Identified and Tested
1. Epidemiology: Cohort studies (follow exposed and unexposed groups forward; produce relative risk and standardized mortality ratios) and case-control studies (compare exposure histories of diseased and non-diseased individuals; produce odds ratios). Human data carry the most weight.
2. Long-term animal bioassays: Typically two-year studies in two rodent species at several doses including a maximum tolerated dose (MTD). Results are extrapolated to humans using low-dose models.
3. Short-term genotoxicity tests: The Ames test (bacterial reverse mutation assay using Salmonella typhimurium strains with and without liver S9 metabolic activation) is the classic mutagenicity screen. Others include chromosomal aberration assays, micronucleus tests, sister chromatid exchange and the comet assay. A positive mutagenicity result flags a potential carcinogen.
4. Developmental toxicity studies: Segment II studies dose pregnant animals during organogenesis and examine offspring for malformations, growth retardation and death.
5. Structure-activity relationships (SAR): Chemicals with structures similar to known carcinogens (for example, aromatic amines, nitrosamines, epoxides, alkylating agents) are suspected until tested.

Dose-Response and Risk Concepts
For genotoxic carcinogens regulators generally assume a linear no-threshold (LNT) model, meaning any exposure carries some risk and the goal is to reduce exposure to as low as reasonably achievable (ALARA, a term borrowed from radiation protection). Risk is often expressed as excess lifetime cancer risk; one in one million (1 x 10 to the minus 6) is a common regulatory target, while OSHA has historically used one in one thousand over a working lifetime as a benchmark for significant risk under the Benzene decision (1980). For teratogens and non-genotoxic carcinogens, a threshold model with a NOAEL (no observed adverse effect level), LOAEL (lowest observed adverse effect level) and uncertainty factors is applied. Latency is the time between first exposure and disease onset; for solid tumors it is commonly 20 to 40 years, for leukemias often 5 to 15 years, and for mesothelioma 30 to 40 years. Latency explains why workplaces with no current cases may still have a serious problem.

Classic Agent-Disease Pairings (High Yield)
Asbestos: mesothelioma, lung cancer, asbestosis (not cancer), gastrointestinal cancers.
Benzene: acute myeloid leukemia, aplastic anemia.
Vinyl chloride monomer: angiosarcoma of the liver.
Hexavalent chromium: lung cancer, nasal septum perforation.
Beta-naphthylamine, benzidine, 4-aminobiphenyl (aromatic amines): bladder cancer.
Arsenic: skin and lung cancer.
Beryllium: lung cancer and chronic beryllium disease.
Cadmium: lung and prostate cancer, kidney damage.
Nickel compounds: nasal and lung cancer.
Formaldehyde: nasopharyngeal cancer, leukemia.
Crystalline silica: lung cancer, silicosis.
Wood dust: nasal adenocarcinoma.
Radon and uranium mining: lung cancer.
Ultraviolet radiation: skin cancer (melanoma and non-melanoma).
Coal tar, soot, polycyclic aromatic hydrocarbons: skin and scrotal cancer (Percivall Pott, chimney sweeps, 1775, the first recognized occupational cancer).
Ethylene oxide: leukemia, lymphoma; also a mutagen and reproductive toxicant.
Lead: reproductive toxicant for both sexes, neurodevelopmental effects in the fetus and child; OSHA lead standard requires medical removal protection.
Methylmercury: cerebral palsy-like damage in offspring (Minamata).
Thalidomide: limb reduction defects (phocomelia), the event that transformed teratology.
DBCP (dibromochloropropane): male sterility.
Glycol ethers (2-methoxyethanol, 2-ethoxyethanol): testicular toxicity and birth defects.
Ionizing radiation: carcinogen, mutagen and teratogen (one of the few agents clearly in all three categories).

Control Strategies
Follow the hierarchy of controls: elimination and substitution first (replace benzene with toluene or a less hazardous solvent; replace a chromate primer), then engineering controls (closed systems, local exhaust ventilation, glove boxes, isolation), administrative controls (regulated areas with restricted access and warning signs, written exposure control plans, training, rotation is generally not appropriate for carcinogens because it spreads risk rather than reducing it), and finally personal protective equipment. Key programmatic elements required by OSHA carcinogen standards include: exposure monitoring with action levels and PELs, regulated areas, hygiene facilities and prohibitions on eating or smoking in regulated areas, protective clothing with on-site laundering (never taking contaminated clothing home, a classic cause of take-home exposure to families), medical surveillance including baseline and periodic exams and biological monitoring where available, medical removal protection (lead, cadmium, benzene, methylene chloride, formaldehyde), recordkeeping for exposure records (30 years) and medical records (duration of employment plus 30 years), hazard communication with SDS and labels, and employee training. For reproductive hazards, employers should provide information and voluntary accommodation rather than excluding fertile workers, consistent with Johnson Controls.

Exam Tips: Answering Questions on Carcinogens, Mutagens and Teratogens
1. Match the keyword to the term. If the stem mentions cancer, tumors or malignancy, the answer is carcinogen. If it mentions DNA, chromosomes, genes, heritable or offspring of exposed workers inheriting a defect, the answer is mutagen. If it mentions birth defects, the embryo, the fetus, pregnancy or congenital malformation, the answer is teratogen. If it mentions fertility, sterility, sperm count or menstrual disorders, the broader answer is reproductive toxicant.
2. Know the relationships. All genotoxic carcinogens are mutagens; not all mutagens are proven carcinogens; teratogens do not have to be mutagens or carcinogens (thalidomide is a teratogen but not a mutagen). Ionizing radiation is the standard example of an agent that is all three.
3. Memorize the classification ladders. IARC 1, 2A, 2B, 3 (Group 4 discontinued); NTP known versus reasonably anticipated; ACGIH A1 through A5; GHS Categories 1A, 1B, 2. A frequent trick is to swap ACGIH A2 (suspected human) with A3 (confirmed animal). Another is to assign Group 1 to probable rather than confirmed.
4. Remember threshold versus no-threshold. Genotoxic carcinogens are modeled as having no threshold (linear no-threshold, ALARA); teratogens and non-genotoxic carcinogens are assumed to have a threshold. If a question asks which class has a well-defined safe level, teratogens is the likely answer.
5. Timing questions for teratogens. The period of greatest sensitivity for structural birth defects is organogenesis, roughly weeks 3 through 8 of gestation (the embryonic period). Pre-implantation is all-or-none; the fetal period is associated with growth and functional (especially CNS) effects.
6. Latency. If asked why an occupational cancer cluster appears decades after a plant changed processes, the answer is latency, typically 10 to 40 years. Leukemia has shorter latency than solid tumors.
7. Hazard Communication thresholds. Carcinogens must appear on the SDS at 0.1 percent or greater; most other hazards at 1 percent. Hazard statement codes: H350 cancer, H340 genetic defects, H360 fertility or unborn child. All use the health hazard pictogram and Category 1 uses the signal word Danger.
8. Agent-disease pairings. Expect at least one question of the form: workers at a polymerization plant developed a rare liver tumor; which agent is responsible? (vinyl chloride, angiosarcoma). Or dye workers developed bladder cancer (aromatic amines such as benzidine or beta-naphthylamine). Or insulation workers developed mesothelioma (asbestos). Or rubber or petrochemical workers developed leukemia (benzene).
9. Test methods. The Ames test is a bacterial mutagenicity screen, not a cancer test and not a teratogenicity test. A positive Ames result means the substance is a suspected carcinogen requiring further evaluation. Two-year rodent bioassays and human epidemiology establish carcinogenicity; cohort studies yield relative risk and case-control studies yield odds ratios.
10. Control hierarchy logic. For a confirmed human carcinogen the best first choice is always elimination or substitution, followed by enclosure and local exhaust ventilation. Worker rotation is a distractor that is inappropriate for carcinogens. Respirators are the last resort. Regulated areas, signage, prohibitions on eating and smoking, on-site laundering and medical surveillance are standard elements of OSHA carcinogen standards.
11. Legal and policy traps. Fetal protection policies that exclude fertile women were struck down in UAW v. Johnson Controls; the correct approach is to reduce exposure for everyone and provide information so workers can make informed choices. OSHA exposure records must be kept 30 years; medical records for duration of employment plus 30 years.
12. Synergism and promotion. Asbestos plus smoking is the classic example of multiplicative (synergistic) risk. Promoters do not initiate cancer, act reversibly and require prior initiation; initiators act irreversibly on DNA.
13. Read qualifiers carefully. Words such as most sensitive, first step, best, primary and least likely change the answer. When two options look correct, choose the one that is most specific to the stem (for example, the specific GHS category rather than the general hazard class).
14. Use elimination. Discard options that confuse acute and chronic effects (irritation or narcosis are not carcinogenic endpoints), that misuse terms (mutagenic birth defect is a mixed-up phrase), or that propose administrative solutions when engineering controls are feasible.
15. Expect integration with other IH topics. Questions may combine carcinogen knowledge with TLV notations (A1 plus Skin notation), with sampling strategy (sampling at the action level triggers periodic monitoring and medical surveillance), with radiation (ALARA, stochastic versus deterministic effects, where cancer and heritable effects are stochastic and birth defects at high dose are deterministic), and with biological monitoring (blood lead, urinary phenol for benzene historically, urinary S-phenylmercapturic acid currently).

Quick Review Summary
Carcinogen = cancer; mutagen = DNA change (somatic leads to cancer, germ cell leads to heritable defects); teratogen = birth defects from exposure during pregnancy, most sensitive during organogenesis at weeks 3 to 8. Genotoxic carcinogens are assumed to have no threshold; teratogens have thresholds. IARC Groups 1, 2A, 2B, 3; NTP known or reasonably anticipated; ACGIH A1 to A5; GHS 1A, 1B, 2 with H350/H340/H360 and the health hazard pictogram. Carcinogens are disclosed on SDSs at 0.1 percent. Latency is 10 to 40 years. Classic pairings: asbestos and mesothelioma, benzene and leukemia, vinyl chloride and liver angiosarcoma, aromatic amines and bladder cancer, hexavalent chromium and lung cancer, thalidomide and phocomelia, methylmercury and fetal neurological damage, lead and reproductive or developmental harm, DBCP and male sterility. Control by elimination and substitution first, engineering controls second, regulated areas and medical surveillance as required by OSHA standards, and never rely on worker rotation for carcinogens. Master these points and you will be well prepared for every question the ASP exam is likely to ask on this topic.